TriSalus Life Sciences (TLSI) Cash & Equivalents (2020 - 2026)

TriSalus Life Sciences' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $56.6 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 335.02% year-over-year to $56.6 million in Q1 2026; TTM through Mar 2026 was $56.6 million, a 335.02% increase from a year earlier, with the FY2025 full-year figure at $20.4 million, up 139.75% from the prior year.
• Cash & Equivalents advanced to $56.6 million in Q1 2026 per TLSI's latest filing, from $20.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $56.6 million in Q1 2026 and bottomed at $69182.0 in Q2 2022.
• The 5-year median for Cash & Equivalents is $11.8 million (2023), against an average of $14.8 million.
• Across the five-year window, Cash & Equivalents tumbled 89.24% in 2022 and jumped 15750.93% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $9.4 million in 2022, then rose by 25.1% to $11.8 million in 2023, then decreased by 27.61% to $8.5 million in 2024, then soared by 139.75% to $20.4 million in 2025, then soared by 176.69% to $56.6 million in 2026.
• Per Business Quant, the three latest TLSI Cash & Equivalents figures stand at $56.6 million (Q1 2026), $20.4 million (Q4 2025), and $22.7 million (Q3 2025).